300760 迈瑞医疗
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入9,372,81112.06%34,931,90130,365,64425,269,58121,025,846
减:营业总成本6,073,4728.99%21,991,20519,826,76016,667,53913,900,566
    其中:营业成本3,190,13113.50%11,820,70810,885,2898,842,7157,366,094
               财务费用(123,736)2,005.68%(854,912)(451,037)(85,973)(61,421)
               资产减值损失(43,449)2.10%(529,506)(71,094)(131,734)(110,250)
公允价值变动收益126,028--79,402(21,378)9,879--
投资收益(3,099)183.94%(9,841)(5,061)811(4,471)
    其中:对联营企业和合营企业的投资收益(3,099)183.94%(9,817)(4,698)811(4,471)
营业利润3,572,27923.20%13,069,85810,990,5159,065,7177,455,160
利润总额3,557,71523.21%13,010,93010,953,5519,017,0857,438,440
减:所得税费用395,92425.59%1,432,5171,342,8341,013,039778,837
净利润3,161,79122.92%11,578,4139,610,7178,004,0466,659,603
减:非控股权益1,89254.87%(3,813)3,5432,4921,927
股东净利润3,159,89922.90%11,582,2269,607,1748,001,5546,657,676

市场价值指针
每股收益 (元) *2.61122.80%9.5597.9406.5875.477
每股派息 (元) *----5.8004.5003.5002.500
每股净资产 (元) *29.8364.39%27.28826.37722.17119.148
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容